Joseph R Podojil

List of Publications by Year
in descending order

54 papers	2,865 citations	172457 29 h-index	223800 46 g-index
78 all docs	78 docs citations	78 times ranked	4608 citing authors

#	Article	IF	Citations
1	Masked Delivery of Allergen in Nanoparticles Safely Attenuates Anaphylactic Response in Murine Models of Peanut Allergy. Frontiers in Allergy, 2022, 3, 829605.	2.8	9
2	ONP-302 Nanoparticles Inhibit Tumor Growth By Altering Tumor-Associated Macrophages And Cancer-Associated Fibroblasts. Journal of Cancer, 2022, 13, 1933-1944.	2.5	6
3	Nanoparticles reduce monocytes within the lungs to improve outcomes after influenza virus infection in aged mice. JCI Insight, 2022, 7, .	5.0	1
4	Tolerogenic Immune-Modifying Nanoparticles Encapsulating Multiple Recombinant Pancreatic Î² Cell Proteins Prevent Onset and Progression of Type 1 Diabetes in Nonobese Diabetic Mice. Journal of Immunology, 2022, 209, 465-475.	0.8	7
5	Repurposing the cardiac glycoside digoxin to stimulate myelin regeneration in <scp>chemicallyâ€induced</scp> and <scp>immuneâ€mediated</scp> mouse models of multiple sclerosis. Glia, 2022, 70, 1950-1970.	4.9	7
6	TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study. Gastroenterology, 2021, 161, 66-80.e8.	1.3	88
7	Tolerance Induced by Antigen-Loaded PLG Nanoparticles Affects the Phenotype and Trafficking of Transgenic CD4+ and CD8+ T Cells. Cells, 2021, 10, 3445.	4.1	4
8	Pre-clinical and Clinical Implications of â€œInside-Outâ€•vs. â€œOutside-Inâ€•Paradigms in Multiple Sclerosis Etiopathogenesis. Frontiers in Cellular Neuroscience, 2020, 14, 599717.	3.7	46
9	630 TAK-101 (TIMP-GLIA) PREVENTS GLUTEN CHALLENGE INDUCED IMMUNE ACTIVATION IN ADULTS WITH CELIAC DISEASE. Gastroenterology, 2020, 158, S-135.	1.3	2
10	Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma. OncoImmunology, 2020, 9, 1744897.	4.6	25
11	Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clinical Cancer Research, 2020, 26, 5232-5245.	7.0	52
12	Gliadin Nanoparticles Induce Immune Tolerance to Gliadin in Mouse Models of Celiac Disease. Gastroenterology, 2020, 158, 1667-1681.e12.	1.3	87
13	Methodology for in vitro Assessment of Human T Cell Activation and Blockade. Bio-protocol, 2020, 10, e3644.	0.4	0
14	Sephin1, which prolongs the integrated stress response, is a promising therapeutic for multiple sclerosis. Brain, 2019, 142, 344-361.	7.6	55
15	Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 18, 282-291.	3.3	67
16	Abstract 2405: B7H4 as a T cell inhibitory regulator in bladder cancer. , 2019, , .		0
17	Abstract 2405: B7H4 as a T cell inhibitory regulator in bladder cancer. , 2019, , .		0
18	Peripherally derived T regulatory and Î³Î´ T cells have opposing roles in the pathogenesis of intractable pediatric epilepsy. Journal of Experimental Medicine, 2018, 215, 1169-1186.	8.5	80

#	Article	IF	Citations
19	ILDR2-Fc Is a Novel Regulator of Immune Homeostasis and Inducer of Antigen-Specific Immune Tolerance. Journal of Immunology, 2018, 200, 2013-2024.	0.8	17
20	ILDR2 Is a Novel B7-like Protein That Negatively Regulates T Cell Responses. Journal of Immunology, 2018, 200, 2025-2037.	0.8	26
21	Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells. Journal of Autoimmunity, 2018, 89, 112-124.	6.5	87
22	B7-H4 Modulates Regulatory CD4+ T Cell Induction and Function via Ligation of a Semaphorin 3a/Plexin A4/Neuropilin-1 Complex. Journal of Immunology, 2018, 201, 897-907.	0.8	34
23	APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response. Oncotarget, 2018, 9, 4537-4548.	1.8	92
24	Potential targeting of B7â€H4 for the treatment of cancer. Immunological Reviews, 2017, 276, 40-51.	6.0	103
25	MP44-05 OVEREXPRESSION OF IMMUNE CO-STIMULATORY MOLECULE B7-H4 IS ASSOCIATED WITH POOR SURVIVAL IN BLADDER UROTHELIAL CARCINOMA. Journal of Urology, 2017, 197, .	0.4	0
26	Pattern of CXCR7 Gene Expression in Mouse Brain Under Normal and Inflammatory Conditions. Journal of NeuroImmune Pharmacology, 2016, 11, 26-35.	4.1	39
27	Cutting Edge: CD99 Is a Novel Therapeutic Target for Control of T Cellâ€"Mediated Central Nervous System Autoimmune Disease. Journal of Immunology, 2016, 196, 1443-1448.	0.8	20
28	Oligodendrocyte death results in immune-mediated CNS demyelination. Nature Neuroscience, 2016, 19, 65-74.	14.8	145
29	ER Chaperone BiP/GRP78 Is Required for Myelinating Cell Survival and Provides Protection during Experimental Autoimmune Encephalomyelitis. Journal of Neuroscience, 2015, 35, 15921-15933.	3.6	41
30	Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. Nature, 2015, 522, 216-220.	27.8	336
31	Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic. Nature Communications, 2015, 6, 6532.	12.8	87
32	Integrin/Chemokine Receptor Interactions in the Pathogenesis of Experimental Autoimmune Encephalomyelitis. Journal of NeuroImmune Pharmacology, 2014, 9, 438-445.	4.1	10
33	Targeting the B7 Family of Co-Stimulatory Molecules. BioDrugs, 2013, 27, 1-13.	4.6	42
34	B7-H4Ig inhibits mouse and human T-cell function and treats EAE via IL-10/Treg-dependent mechanisms. Journal of Autoimmunity, 2013, 44, 71-81.	6.5	49
35	Identification of novel immune checkpoints as targets for cancer immunotherapy. , 2013, 1, .		0
36	Abstract B291: Identification of novel immune checkpoints and their implementation as mAb targets for cancer immunotherapy.. , 2013, , .		0

#	Article	IF	Citations
37	Virus expanded regulatory T cells control disease severity in the Theilerâ€™s virus mouse model of MS. Journal of Autoimmunity, 2011, 36, 142-154.	6.5	59
38	Combination treatment of mice with crx-153 (nortriptyline and desloratadine) decreases the severity of experimental autoimmune encephalomyelitis. Cellular Immunology, 2011, 270, 237-250.	3.0	4
39	TGF-Î²â€"Induced Myelin Peptide-Specific Regulatory T Cells Mediate Antigen-Specific Suppression of Induction of Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2010, 184, 6629-6636.	0.8	42
40	A genetic mouse model of adult-onset, pervasive central nervous system demyelination with robust remyelination. Brain, 2010, 133, 3017-3029.	7.6	101
41	OR.103. Induced PLP Peptide-specific Regulatory T Cells Appear to Suppress Experimental Autoimmune Encephalomyelitis in an Antigen-specific Manner. Clinical Immunology, 2009, 131, S42.	3.2	0
42	Molecular mechanisms of Tâ€cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunological Reviews, 2009, 229, 337-355.	6.0	115
43	Cross-Linking of CD80 on CD4+ T Cells Activates a Calcium-Dependent Signaling Pathway. Journal of Immunology, 2009, 182, 766-773.	0.8	9
44	Intrinsic and Induced Regulation of the Age-Associated Onset of Spontaneous Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2008, 181, 4638-4647.	0.8	41
45	Therapeutic Blockade of T- Cell Antigen Receptor Signal Transduction and Costimulation in Autoimmune Disease. Advances in Experimental Medicine and Biology, 2008, 640, 234-251.	1.6	11
46	Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nature Reviews Immunology, 2007, 7, 665-677.	22.7	252
47	Immunopathological mechanisms in multiple sclerosis. Drug Discovery Today Disease Mechanisms, 2006, 3, 177-184.	0.8	2
48	Cutting Edge: Anti-CD25 Monoclonal Antibody Injection Results in the Functional Inactivation, Not Depletion, of CD4+CD25+ T Regulatory Cells. Journal of Immunology, 2006, 176, 3301-3305.	0.8	296
49	CD4+ T Cell Expressed CD80 Regulates Central Nervous System Effector Function and Survival during Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2006, 177, 2948-2958.	0.8	25
50	CD28 regulates glucocorticoid-induced TNF receptor family-related gene expression on CD4+ T cells via IL-2-dependent mechanisms. Cellular Immunology, 2005, 235, 56-64.	3.0	27
51	CD86 and Î²2-adrenergic receptor stimulation regulate B-cell activity cooperatively. Trends in Immunology, 2005, 26, 180-185.	6.8	35
52	CD86 and Î²2-Adrenergic Receptor Signaling Pathways, Respectively, Increase Oct-2 and OCA-B Expression and Binding to the 3â€²-IgH Enhancer in B Cells. Journal of Biological Chemistry, 2004, 279, 23394-23404.	3.4	62
53	Adaptive immunity in mice lacking the Î²2-adrenergic receptor. Brain, Behavior, and Immunity, 2003, 17, 55-67.	4.1	46
54	Selective Regulation of Mature IgG1 Transcription by CD86 and Î²2-Adrenergic Receptor Stimulation. Journal of Immunology, 2003, 170, 5143-5151.	0.8	74